Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the ...

No company has had a more profound impact on inherited breast and ovarian cancer than Myriad Genetics. Its DNA test to identify women with a sharply increased chance of developing these cancers ...

Myriad Genetics believes the "golden age" of personalized medicine is here. It has captured 90% of the molecular diagnostics market. Yet, the market is still full of potential. Accurate testing ...

SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen ...

One prominent one, sold by the genetic-testing company Myriad Genetics, analyzes a patient's DNA to point a doctor to the best options or doses of drugs like Zoloft and Paxil for an individual ...

Image source: Myriad Genetics. April showers bring myriad flowers. That's not really how the old adage goes, but the changed wording just might be applicable to Myriad Genetics. Shares of the ...